Endologix Appoints New VP of Clinical Affairs

Irvine, Calif.-based Endologix Inc. has named Charles Love as its new vice president of clinical affairs. Love will be responsible for overseeing all Endologix U.S. and international clinical trials, and will report to John McDermott, president and CEO. Janet Fauls, previously vice president of regulatory and clinical affairs, will maintain responsibility for overseeing regulatory affairs as the company prepares for multiple upcoming potential regulatory milestones for its product pipeline.

“Charles Love has more than 20 years of experience with medical devices in product development, regulatory strategy and clinical trial design,” said McDermott. “His extensive experience will be a valuable asset as we continue to advance our new product pipeline, including the U.S. clinical trials for the Ventana Fenestrated System and the Nellix EndoVascular Aneurysm Sealing System. We look forward to Love joining our management team as we continue to expand our product portfolio and gain share in the AAA [abdominal aortic aneurysm] market.”

Prior to joining Endologix, Love served as vice president of clinical and regulatory compliance at CircuLite Inc., a privately held medical device company developing disruptive solutions for the treatment of chronic heart failure. He has also served as a consultant and held management level clinical affairs, regulatory and strategic development positions for a variety of medical device companies, including Medtronic Inc., CoreValve, nContact Surgical Inc., Ventracor Limited, and Converge Medical Inc. His experience also includes senior management positions at Ramus Medical Technologies and Autogenics. He serves on the board of directors for Loma Vista Medical in Burlingame, Calif., and is on the technical advisory board for Dexteritie Surgical.

Love received a B.A. in biology from Westmont College in Montecito, Calif. He also completed undergraduate work in engineering at Gonzaga University in Spokane, Wash., and completed management programs at the University of California and Stanford University.

Endologix makes treatments for aortic disorders. Currently, the Nellix EndoVascular Aneurysm Sealing System is not approved in the United States. The Ventana Fenestrated System is an investigational device in the United States and internationally.